TABLE 2.
Metabolic pathways significantly altered between groups.
| Group | Pathway | −log(P) | Impact | Hits | Compounds |
|---|---|---|---|---|---|
| RCC vs. BKT | Glycerophospholipid metabolism | 11.10 | 0.44 | 8 | PE 21:5, PC 34:2, LPC 19:2, PA 23:2, PS 18:3, PG 14:0, LPG 18:3 and PI 18:4 |
| Phosphatidylinositol signaling system | 1.39 | 0.10 | 2 | PI 18:4 and PA 23:2 | |
| D-Glutamine and d-glutamate metabolism | 1.67 | 0.50 | 1 | Glutamic acid | |
| RCC vs. HC | Glycerophospholipid metabolism | 9.65 | 0.46 | 10 | PE 21:5, PC (34:2), LPC 19:2, Choline, PA 23:2, PS 18:3, LPE 16:0, LPI 18:5, LPG 24:0 and PI 16:0 |
| Glycerolipid metabolism | 8.48 | 0.22 | 3 | PA 23:2, MG (18:1) and MGDG 22:3 | |
| D-Glutamine and d-glutamate metabolism | 2.90 | 1.00 | 1 | Glutamic acid | |
| BKT vs. HC | Glycerophospholipid metabolism | 8.77 | 0.46 | 8 | PE 22:1, PC 34:2, LPC 19:2, PA 23:3, PS 23:4, LPE 20:1, PG 14:0 and PI 16:0 |
Note: HC, healthy control; BKT, benign kidney tumor; RCC, renal cell carcinoma; PE, phosphatidylethanolamine; PC, phosphatidylcholine; LPC, lysophosphatidylcholine; PA, phosphatidic acid; PS, phosphatidylserine; LPE, lysophosphatidylethanolamine; LPI, lysophosphatidylinositol; LPG, lysophosphatidylglycerol; PI, phosphatidylinositol; MG, monoglyceride; MGDG, monogalactosyldiglyceride. -log(P), negative logarithm of the p-value of the statistic; Impact, impact value of metabolic pathway determined by topology analysis; Hits, the number of differential metabolites matching the pathway.